These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 29859176)

  • 1. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.
    Choi MY; Widhopf GF; Ghia EM; Kidwell RL; Hasan MK; Yu J; Rassenti LZ; Chen L; Chen Y; Pittman E; Pu M; Messer K; Prussak CE; Castro JE; Jamieson C; Kipps TJ
    Cell Stem Cell; 2018 Jun; 22(6):951-959.e3. PubMed ID: 29859176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.
    Hasan MK; Yu J; Chen L; Cui B; Widhopf Ii GF; Rassenti L; Shen Z; Briggs SP; Kipps TJ
    Leukemia; 2017 Dec; 31(12):2615-2622. PubMed ID: 28465529
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Rassenti LZ; Balatti V; Ghia EM; Palamarchuk A; Tomasello L; Fadda P; Pekarsky Y; Widhopf GF; Kipps TJ; Croce CM
    Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10731-10736. PubMed ID: 28923920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells.
    Hasan MK; Rassenti L; Widhopf GF; Yu J; Kipps TJ
    Leukemia; 2019 Mar; 33(3):653-661. PubMed ID: 30568170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia.
    Chen Y; Chen L; Yu J; Ghia EM; Choi MY; Zhang L; Zhang S; Sanchez-Lopez E; Widhopf GF; Messer K; Rassenti LZ; Jamieson C; Kipps TJ
    Blood; 2019 Sep; 134(13):1084-1094. PubMed ID: 31409670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.
    Yu J; Chen L; Cui B; Wu C; Choi MY; Chen Y; Zhang L; Rassenti LZ; Widhopf Ii GF; Kipps TJ
    Leukemia; 2017 Jun; 31(6):1333-1339. PubMed ID: 27904138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism.
    Hasan MK; Ghia EM; Rassenti LZ; Widhopf GF; Kipps TJ
    Leukemia; 2021 Jun; 35(6):1621-1630. PubMed ID: 33097837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia.
    Hasan MK; Yu J; Widhopf GF; Rassenti LZ; Chen L; Shen Z; Briggs SP; Neuberg DS; Kipps TJ
    Blood; 2018 Jul; 132(2):170-178. PubMed ID: 29678828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.
    Yu J; Chen L; Chen Y; Hasan MK; Ghia EM; Zhang L; Wu R; Rassenti LZ; Widhopf GF; Shen Z; Briggs SP; Kipps TJ
    Leukemia; 2017 Dec; 31(12):2608-2614. PubMed ID: 28465528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.
    Yu J; Chen L; Cui B; Widhopf GF; Shen Z; Wu R; Zhang L; Zhang S; Briggs SP; Kipps TJ
    J Clin Invest; 2016 Feb; 126(2):585-98. PubMed ID: 26690702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.
    Cui B; Ghia EM; Chen L; Rassenti LZ; DeBoever C; Widhopf GF; Yu J; Neuberg DS; Wierda WG; Rai KR; Kay NE; Brown JR; Jones JA; Gribben JG; Frazer KA; Kipps TJ
    Blood; 2016 Dec; 128(25):2931-2940. PubMed ID: 27815263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia.
    Ghia EM; Rassenti LZ; Choi MY; Quijada-Álamo M; Chu E; Widhopf GF; Kipps TJ
    Leukemia; 2022 Jun; 36(6):1609-1618. PubMed ID: 35418613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia.
    Sanchez-Lopez E; Ghia EM; Antonucci L; Sharma N; Rassenti LZ; Xu J; Sun B; Kipps TJ; Karin M
    Cell Death Differ; 2020 Jul; 27(7):2206-2216. PubMed ID: 31992855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1.
    Choi MY; Widhopf GF; Wu CC; Cui B; Lao F; Sadarangani A; Cavagnaro J; Prussak C; Carson DA; Jamieson C; Kipps TJ
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S167-9. PubMed ID: 26297272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
    Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
    Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How receptor tyrosine kinase-like orphan receptor 1 meets its partners in chronic lymphocytic leukemia.
    Mouawad N; Ruggeri E; Capasso G; Martinello L; Visentin A; Frezzato F; Trentin L
    Hematol Oncol; 2024 Mar; 42(2):e3250. PubMed ID: 38949887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting ROR1 identifies new treatment strategies in hematological cancers.
    Karvonen H; Niininen W; Murumägi A; Ungureanu D
    Biochem Soc Trans; 2017 Apr; 45(2):457-464. PubMed ID: 28408486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.
    Daneshmanesh AH; Hojjat-Farsangi M; Khan AS; Jeddi-Tehrani M; Akhondi MM; Bayat AA; Ghods R; Mahmoudi AR; Hadavi R; Österborg A; Shokri F; Rabbani H; Mellstedt H
    Leukemia; 2012 Jun; 26(6):1348-55. PubMed ID: 22289919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
    Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.
    Zhang S; Zhang H; Ghia EM; Huang J; Wu L; Zhang J; Lam S; Lei Y; He J; Cui B; Widhopf GF; Yu J; Schwab R; Messer K; Jiang W; Parker BA; Carson DA; Kipps TJ
    Proc Natl Acad Sci U S A; 2019 Jan; 116(4):1370-1377. PubMed ID: 30622177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.